TradeLink Capital LLC Purchases Shares of 2,700 Neurocrine Biosciences, Inc. (NBIX)

TradeLink Capital LLC purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, Holdings Channel reports. The firm purchased 2,700 shares of the company’s stock, valued at approximately $332,000. Neurocrine Biosciences makes up approximately 1.5% of TradeLink Capital LLC’s holdings, making the stock its 18th biggest position.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NBIX. Meeder Asset Management Inc. grew its stake in shares of Neurocrine Biosciences by 643.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock valued at $110,000 after buying an additional 972 shares in the last quarter. TRUE Private Wealth Advisors bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $127,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $127,000. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Neurocrine Biosciences by 103.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,016 shares of the company’s stock valued at $167,000 after buying an additional 1,025 shares in the last quarter. Finally, Financial Architects Inc grew its stake in shares of Neurocrine Biosciences by 283.7% in the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock valued at $170,000 after buying an additional 1,024 shares in the last quarter.

In other news, Director Gary A. Lyons sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $114.41, for a total transaction of $1,716,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard F. Pops sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, October 29th. The stock was sold at an average price of $107.13, for a total value of $589,215.00. Following the transaction, the director now owns 37,759 shares of the company’s stock, valued at $4,045,121.67. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Several research firms recently weighed in on NBIX. Cantor Fitzgerald began coverage on Neurocrine Biosciences in a report on Wednesday, August 22nd. They issued an “overweight” rating and a $150.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $162.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, August 1st. Oppenheimer set a $128.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, July 31st. BidaskClub upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday, July 27th. Finally, ICAP reduced their target price on Neurocrine Biosciences from $140.00 to $128.00 and set an “outperform” rating for the company in a report on Tuesday, September 4th. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $124.88.

NBIX opened at $108.30 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $67.32 and a twelve month high of $126.98. The company has a market capitalization of $9.66 billion, a P/E ratio of -66.85, a P/E/G ratio of 38.23 and a beta of 0.94.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, November 5th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.04. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. The company had revenue of $151.80 million during the quarter, compared to analyst estimates of $151.51 million. During the same period in the previous year, the company earned ($0.13) earnings per share. The company’s quarterly revenue was up 149.7% compared to the same quarter last year. Analysts predict that Neurocrine Biosciences, Inc. will post 0.13 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “TradeLink Capital LLC Purchases Shares of 2,700 Neurocrine Biosciences, Inc. (NBIX)” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.wkrb13.com/2018/11/09/tradelink-capital-llc-purchases-shares-of-2700-neurocrine-biosciences-inc-nbix.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Featured Article: Find a Trading Strategy That Works

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply